SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance.

Zexuan LiuJunhao LiuBehnam EbrahimiUday P PratapYi HeKristin A AltweggWeiwei TangXiaonan LiZhao LaiYidong ChenLiangfang ShenGangadhara R SareddySuryavathi ViswanadhapalliRajeshwar R TekmalManjeet K RaoRatna K Vadlamudi

Published in: Breast cancer research : BCR (2022)

This study suggests that the PELP1/SETDB1 axis play an important role in aberrant Akt activation and serves as a novel target for treating endocrine therapy resistance in breast cancer.

Keyphrases

signaling pathway
cell proliferation
stem cells
young adults
mesenchymal stem cells
bone marrow
breast cancer risk